Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIS trial: MRD-tailored first-line venetoclax + obinutuzumab with response-adapted venetoclax or venetoclax + zanubrutinib in young high-risk CLL
2023-510431-11-00Phase 2Authorised
- Sponsor
- GIMEMA
- Start
- Jul 2023
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of venetoclax, obinutuzumab and zanubrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (3 arms), sponsored by GIMEMA. Planned start Jul 2023; status: authorised.
02
Drugs
venetoclaxobinutuzumabzanubrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2023-510431-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510431-11-00.